Sigma Investment Counselors Inc. Sells 154 Shares of Danaher Co. (NYSE:DHR)

Sigma Investment Counselors Inc. trimmed its stake in Danaher Co. (NYSE:DHR) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,623 shares of the conglomerate’s stock after selling 154 shares during the quarter. Sigma Investment Counselors Inc.’s holdings in Danaher were worth $7,958,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Good Life Advisors LLC bought a new position in Danaher during the third quarter valued at $217,000. Oak Thistle LLC bought a new position in shares of Danaher during the 2nd quarter worth $363,000. Norden Group LLC purchased a new stake in Danaher in the 1st quarter worth about $4,151,000. Duality Advisers LP bought a new stake in Danaher in the 1st quarter valued at about $5,573,000. Finally, Diversified Trust Co lifted its holdings in Danaher by 75.4% during the second quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock valued at $1,090,000 after purchasing an additional 1,874 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Down 1.0 %

NYSE:DHR opened at $245.41 on Friday. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The company has a market cap of $181.77 billion, a PE ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. The company’s 50 day moving average is $269.52 and its two-hundred day moving average is $260.35.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. Analysts anticipate that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on DHR shares. Royal Bank of Canada lowered their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Raymond James reduced their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research report on Wednesday. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.